Search Medical Condition
Please enter condition
Please choose location

Fresno, California Clinical Trials

A listing of Fresno, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (91) clinical trials

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

This is a Phase III, randomized, double-blind, placebo-controlled, parallel group, multi-center, efficacy and safety trial of AM-111 in the treatment of subjects suffering from severe to profound idiopathic sudden sensorineural hearing loss. The active pharmaceutical ingredient of AM-111 is a JNK inhibitor (D-JNKI-1), a synthetic peptide consisting of 31 D-amino ...

Phase

0.0 miles

Learn More »

Safety Tolerability and Efficacy of GS 9674 in Adults With Primary Biliary Cholangitis Without Cirrhosis

The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in adults with primary biliary cholangitis (PBC).

Phase

0.0 miles

Learn More »

Safety Tolerability and Efficacy of GS-9674 in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in adults with primary sclerosing cholangitis (PSC).

Phase

0.0 miles

Learn More »

Fotonovela for Type 2 Diabetes Mellitus

Elevated glucose in diabetics is a risk for amputation, renal failure, coronary artery disease, neuropathy, and blindness. Controlling glucose better as measured by hemoglobin A1c (A1c) reduces risk for these complications. Information itself is often not enough to change behaviors that increase risk for these complications. Latinos in America are ...

Phase N/A

0.0 miles

Learn More »

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer.

Patients will be randomised in 1:1 ratio to either olaparib or placebo. Randomisation will be stratified by Hormone receptor status (ER and/or PgR positive/HER2 negative versus TNBC), prior neoadjuvant versus adjuvant chemotherapy and prior platinum use for breast cancer. Randomised patients will receive study treatment for up to a maximum ...

Phase

0.0 miles

Learn More »

Barostim Therapy for Heart Failure

The purpose of this trial is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy® with the BAROSTIM NEO® System in subjects with heart failure, defined as New York Heart Association (NYHA) functional class III and left ventricular ejection fraction (LVEF) ≤ 35% despite being treated ...

Phase N/A

0.79 miles

Learn More »

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

This is a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 314 patients at approximately ...

Phase

0.79 miles

Learn More »

An Investigational Immuno-therapy Study of Nivolumab Compared to Placebo in Patients With Bladder or Upper Urinary Tract Cancer Following Surgery to Remove the Cancer

The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.

Phase

0.79 miles

Learn More »

Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL Including Patients With MYC Alterations

Patients with RR DLBCL will be eligible for treatment with CUDC-907, as long as they have tumor tissue available that can be tested for MYC-altered disease based on one of the following: - Fresh tumor tissue obtained from biopsy accessible lesions , or - Archived tumor tissue (most recent available) ...

Phase

0.79 miles

Learn More »

Emricasan a Caspase Inhibitor for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

This is a multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of "definite NASH" with fibrosis (excluding cirrhosis) as determined by the central histopathologist. Upon successful screening, subjects will be randomized to receive either emricasan 50 mg BID or emricasan 5 mg BID or matching placebo BID.

Phase

0.79 miles

Learn More »